IPHA
Innate Pharma S.A. ADSstockNASDAQADR
innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.49 | 2026-11-12 | -31.54% | -11.056 |
| 1M | 1.46 | 2026-10-19 | -30.14% | 1.390 |
| 3M | 2.12 | 2026-08-19 | -51.89% | 1.386 |
| 6M | 2.03 | 2026-05-19 | -49.75% | 0.990 |
| 1Y | 1.79 | 2025-11-19 | -43.02% | 1.526 |
| 2Y | 1.49 | 2024-11-19 | -31.54% | — |
| 5Y | 5.01 | 2021-11-19 | -79.64% | 0.176 |
Innate Pharma S.A. ADS (NASDAQ:IPHA) stock price today is $1.02, and today's volume is 503,030. IPHA is down 23.308% today. The 30 day average volume is 37,593. IPHA market cap is $113.93M with 111.70M shares outstanding.